登录

Oceanus Plus Snares ¥10M in Series A+ Round

作者: Mailman 2020-05-18 09:20
铨融医药
http://www.oceanus-plus.com
企业数据由 动脉橙 提供支持
临床试验管理系统研发商 | A+轮 | 运营中
中国-江苏
2020-05-15
融资金额:数千万人民币
幂方健康基金
查看

According to VCBeat, Quanrong (Shanghai) Pharmaceutical Technology Development Co., Ltd. ("Oceanus Plus") has completed the Series A+ financing of tens of millions yuan, led by Med-Fine Capital. WinX Capital acted as the financial adviser.


Oceanus Plus is a SaaS company providing services of clinical trials, such as the clinical trial management system. Oceanus Plus is committed to improving the quality and efficiency of clinical researches.


Oceanus Plus provides comprehensive solutions to help enterprises and hospitals achieve routing and automation in healthcare project management and others. On the basis of the requirements of different regulatory authorities, the company launches products for quality management used in drugs, medical devices, and diagnostic reagents, in accordance with international and Chinese GCP specifications. It provides a full range of services in phase I to IV clinical research, IIT (investigator-initiated trials), RWE (real-world researches), and others.


At the beginning of its establishment, Oceanus Plus has got strategic investment from the Site Management Organization(SMO) company ChinPlus, and the Contract Research Organization (CRO) company Tigermed. So far, the company has cooperated with many leading SMO and CRO companies in the industry in a long term, developing rapidly in products, technologies, services, and applications in hospitals.


Oceanus Plus has built a product system with the S-Trial+ clinical trial central process management platform and the O-trial+ clinical trial execution management platform as the core, which can be applied in more clinical services. The company has passed the ISO27001, ISO13485 certification, in line with the requirements of the level three national information security protection.


Regarding this round of financing, Yang Fan, founder of Oceanus Plus, said that they are confident that the company can provide better products and services with the team's in-depth understanding of the clinical trial industry for enterprises, hospitals and other clients, and continue to contribute to the Chinese pharmaceutical industry.


>>>>

About Med-Fine Capital


Founded in 2014 at China's financial hub-Shanghai, Med-Fine Capital is an investment fund. Currently, it manages11 investment funds, of which the amount value has reached to nearly 800 million yuan.


Med-Fine Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments (VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.

相关赛道 医疗信息化
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

ForceClouds Raises $10 Million Series B Funding, Providing Sales and R&D Management for Medical Company with Cloud Solution

Taimei Technology Completes 1.5 Billion Yuan Series E financing

GenCells Therapeutics Completes ¥10M Pre-A Round of Financing

Chinese Oncology Drug Developer Tot Biopharm Raises $75.2M in HK IPO

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

男性健康管理平台“Menxlab漫仕”获SIG、高榕领投Pre-A数千万元融资

2020-05-18
下一篇

Basecare Closes ¥150M Series C Funding Round

2020-05-18